Nodular Basal Cell Carcinoma Phase-One Trial
Scientia Clinical Research is recruiting adults (aged 18 to 85 years) with untreated nodular basal cell carcinoma to participate in a Phase 1/2a clinical trial. The study is evaluating FLD-103, a novel intralesional Hedgehog pathway inhibitor. This treatment may offer a less invasive alternative to surgery.
Researches from UNSW appreciate referrals of potentially eligible patients who are aged 18 to 85 years and have a diagnosis of untreated nodular basal cell carcinoma. Please contact the study coordinator from Scientia Clinical Research via email for more information: matthew.wong@scientiaclinicalresearch.com.au
Ethics: HREC approved on 07-Aug-2024 as Application 2024-06-773 (lead site), and on 09-Aug-2024 as Application 2024-06-773-AC (Scientia Clinical Research additional site).
iBREAST: Integrated BREast cAncer Survivorship inTerventions in primary care
GPs are invited to provide their perceptions and practices regarding breast cancer survivorship for women living in the community.
Data from this survey may help identify issues and barriers to the provision of evidence based interventions to assist breast cancer survivors manage long-term effects and help inform viable services to meet patient’s needs.
Click here to complete the brief survey.
Ethics: USyd 2024/HE000114
Under the Radar – Black Dog Institute and UNSW
Have you experienced thoughts of ending your life? Complete a 30-minute survey (it’s anonymous) to help researchers at the Black Dog Institute and UNSW to understand your needs, and what a safe and accessible option may look like.
Click here for more information and to complete the survey.
Ageing Well Tool in general practice
Join Macquarie University in trialing the Ageing Well Tool, a screening and early intervention tool designed to identify and reduce risks for dementia and enhance overall wellbeing in primary care patients aged 60-70, to set them up for ageing well.
Click here for more information.